본태성 고혈압 환자에서 S-(-)-Amlodipine Nicotinate와 Ramipril의 유효성 및 안정성의 비교 평가
1
조회
0
다운로드
0
인용
0
참고문헌
초록
Background: The aim of this study was to compare the antihypertensive effect of S-(-)-amlodipine nicotinate with ramipril in patients with essential hypertension. Methods: Total 138 patients (54.5 ± 10.5 years, 69 males) were enrolled in this study between 2008 and 2010. Amlodipine 2.5 mg or ramipril 2.5 mg was treated once in a day for 8 weeks. Epidemiologic analysis was performed in intend-to-treat group. Efficacy analysis was performed in the differences of diastolic blood pressure in study groups. Abnormal reactions were divided with severities and drug-relationship. Results: The change of diastolic blood pressures were more prominent with -12.7 ± 7.02 mm Hg in amlodipine group, and -9.6 ± 7.38 mm Hg in ramipril group (p = 0.023). The change of systolic blood pressures was higher in amlodipine group with -18.1 ± 7.91 mm Hg,and -14.3 ± 11.96 mm Hg in ramipril group (p = 0.047). Blood pressure normalization rates were 81.3% (48 of 59 patients)in amlodipine group, and 61.4% (35 of 57 patients) in ramipril group (p = 0.017). Abnormal reaction occurred in 5.8% (4 of 68 patients) of amlodipine group and 14.2% (10 of 70 patients) of ramipril group (p = 0.102). The most frequent abnormal reaction was respiratory symptom. Conclusions: S-Amlodipine-Nicotinate was more effective than ramipril in hypertensive patients without significant abnormal reaction.
Abstract
Background: The aim of this study was to compare the antihypertensive effect of S-(-)-amlodipine nicotinate with ramipril in patients with essential hypertension. Methods: Total 138 patients (54.5 ± 10.5 years, 69 males) were enrolled in this study between 2008 and 2010. Amlodipine 2.5 mg or ramipril 2.5 mg was treated once in a day for 8 weeks. Epidemiologic analysis was performed in intend-to-treat group. Efficacy analysis was performed in the differences of diastolic blood pressure in study groups. Abnormal reactions were divided with severities and drug-relationship. Results: The change of diastolic blood pressures were more prominent with -12.7 ± 7.02 mm Hg in amlodipine group, and -9.6 ± 7.38 mm Hg in ramipril group (p = 0.023). The change of systolic blood pressures was higher in amlodipine group with -18.1 ± 7.91 mm Hg,and -14.3 ± 11.96 mm Hg in ramipril group (p = 0.047). Blood pressure normalization rates were 81.3% (48 of 59 patients)in amlodipine group, and 61.4% (35 of 57 patients) in ramipril group (p = 0.017). Abnormal reaction occurred in 5.8% (4 of 68 patients) of amlodipine group and 14.2% (10 of 70 patients) of ramipril group (p = 0.102). The most frequent abnormal reaction was respiratory symptom. Conclusions: S-Amlodipine-Nicotinate was more effective than ramipril in hypertensive patients without significant abnormal reaction.
참고문헌 (21)
- Whitworth JA, "World Health Organization, International Society of Hypertension Writing Group. 2003 World Health Organization (WHO)", International Society of Hypertension (ISH) statement on management of hypertension, 2003, pp.21, 1983~1992
- Weber MA, "Hypertension treatment and implications of recent cardiovascular outcome trials", Journal of Hypertension, 24, pp.37~44 (2006)
- Williams B, "Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004-BHS IV", Journal of Human Hypertension, 18, pp.139~185 (2004)
- Chobanian AV, "The seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report", JAMA, 289, pp.2560~2572 (2003)
- Youn JS, "Single center, randomized, single-blind, parallel-group, phase IV clinical trial for the comparison of efficacy and safety between S-(-)-Amlodipine Nicotinate and Lercanidipine HCl in patients with hypertension", Journal of the Korean Society of Hypertension, 16, pp.18~30 (2010)
- Bae JH, "Double-blind, randomized, multi-center trial for the comparison of efficacy and safety between S-amlodipine besylate and Amlodipine besylate in patients with hypertension", Journal of the Korean Society of Hypertension, 14, pp.28~36 (2008)
- Omvik P, "Evaluation and quality-of-life assessment of amlodipine and enalapril in patients with hypertension", Journal of Human Hypertension, 9(1), pp.17~24 (1995)
- Karch FE, "Comparative efficacy and tolerability of two long-acting calcium antagonists, mibefradil and amlodipine, in essential hypertension. Mibefradil Hypertension Study Group", Clinical Therapeutics, 19, pp.1368~1378 (1997)
- Park JY, "Pharmacokinetic and pharmacodynamic characteristics of a new S-amlodipine formulation in healthy Korean male subjects: A randomized, open-label, two-period, comparative, crossover study", CLINICAL THERAPEUTICS, 28, pp.1837~1847
- Perticone F, "Amlodipine versus ramipril in the treatment of mild to moderate hypertension: evaluation by 24-hour ambulatory blood pressure monitoring", Cardiology, 85, pp.36~46 (1994)
- Lund-Johansen P, "Quantification of leg oedema in postmenopausal hypertensive patients treated with lercanidipine or amlodipine", Journal of Hypertension, 21, pp.1003~1010 (2003)
- Kaplan NM, "The CARE Study: a postmarketing evaluation of ramipril in 11,100 patients. The Clinical Altace Real-World Efficacy (CARE) Investigators", Clinical Therapeutics, 18, pp.658~670 (1996)
- ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group, "The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT)", JAMA, 288, pp.2981~2997 (2002)
- Agabiti-Rosei E, "ACE inhibitor ramipril is more effective than the beta-blocker atenolol in reducing left ventricular mass in hypertension. Results of the RACE (ramipril cardioprotective evaluation) study on behalf of the RACE study group", Journal of Hypertension, 13, pp.1325~1334 (1995)
- Fuster RG, "Left ventricular mass index as a prognostic factor in patients with severe aortic stenosis and ventricular dysfunction", Interactive CardioVascular and Thoracic Surgery, 4, pp.260~266 (2005)
- 김응주, "한국인 관상동맥의 직경 및 단면적: 정상치와 결정 인자", Korean Circulation Journal, 35(2), pp.115~122 (2005), 대한심장학회
- Julius S, "VALUE trial: Long-term blood pressure trends in 13,449 patients with hypertension and high cardiovascular risk", American Journal of Hypertension, 16, pp.544~548 (2003)
- Kidney Disease Outcomes Quality Initiative (K, "DOQI)", K, American Journal of Kidney Diseases, pp.2004, 43[DOI]
- 김계훈, "Clinical Effects of Calcium Channel Blocker and Angiotensin Converting Enzyme Inhibitor on Endothelial Function and Arterial Stiffness in Patients with Angina Pectoris", Journal of Korean Medical Science, 24(2), pp.223~231 (2009), 대한의학회
- Mitka M, "CCB", ACE inhibitor dual therapy for hypertension lowers cardiovascular risk, 2008, pp.299, 2263~2264
- Klingbeil AU, "Effect of AT1 receptor blockade on endothelial function in essential hypertension", American Journal of Hypertension, 16, pp.123~128 (2003)